GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acino Holding AG (FRA:S3H) » Definitions » EV-to-EBITDA

Acino Holding AG (FRA:S3H) EV-to-EBITDA : 9.99 (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is Acino Holding AG EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Acino Holding AG's enterprise value is €312.6 Mil. Acino Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2013 was €31.3 Mil. Therefore, Acino Holding AG's EV-to-EBITDA for today is 9.99.

The historical rank and industry rank for Acino Holding AG's EV-to-EBITDA or its related term are showing as below:

FRA:S3H' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0   Med: 0   Max: 13.38
Current: 13.38

During the past 11 years, the highest EV-to-EBITDA of Acino Holding AG was 13.38. The lowest was 0.00. And the median was 0.00.

FRA:S3H's EV-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 14.45 vs FRA:S3H: 13.38

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-24), Acino Holding AG's stock price is €93.92. Acino Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2013 was €-5.410. Therefore, Acino Holding AG's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Acino Holding AG EV-to-EBITDA Historical Data

The historical data trend for Acino Holding AG's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acino Holding AG EV-to-EBITDA Chart

Acino Holding AG Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.47 8.28 9.99 11.93 13.23

Acino Holding AG Semi-Annual Data
Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 4.47 8.28 9.99 11.93 13.23

Competitive Comparison of Acino Holding AG's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Acino Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acino Holding AG's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Acino Holding AG's EV-to-EBITDA falls into.



Acino Holding AG EV-to-EBITDA Calculation

Acino Holding AG's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=312.559/31.299
=9.99

Acino Holding AG's current Enterprise Value is €312.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Acino Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2013 was €31.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acino Holding AG  (FRA:S3H) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Acino Holding AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=93.92/-5.410
=At Loss

Acino Holding AG's share price for today is €93.92.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Acino Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2013 was €-5.410.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Acino Holding AG EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Acino Holding AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Acino Holding AG (FRA:S3H) Business Description

Traded in Other Exchanges
N/A
Address
Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.

Acino Holding AG (FRA:S3H) Headlines

No Headlines